MIST
Milestone Pharmaceuticals Inc.
Company Overview
| Mkt Cap | $140.02M | Price | $1.52 |
| Volume | 2.43M | Change | +9.78% |
| P/E Ratio | -3.4 | Open | $1.41 |
| Revenue | -- | Prev Close | $1.38 |
| Net Income | $-41.5M | 52W Range | $0.63 - $3.06 |
| Div Yield | N/A | Target | $6.60 |
| Overall | 36 | Value | -- |
| Quality | -- | Technical | 36 |
No chart data available
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which completed Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montréal, Canada.
Latest News
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)
Analysts Offer Insights on Healthcare Companies: Rubicon Organics (OtherROMJF), Alcon (ALC) and Milestone Pharmaceuticals (MIST)
Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MIST | $1.52 | +9.8% | 2.43M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Milestone Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW